Pancreatic Cancer: Pathogenesis, Diagnosis, and Laboratory Tests

Authors

  • Rikarni Rikarni Department of Clinical Pathology, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang

DOI:

https://doi.org/10.24293/ijcpml.v27i3.1891

Keywords:

Pancreatic cancer, multistep carcinogenesis, pathogenesis, diagnosis, CA 19-9

Abstract

Pancreatic cancer is the eleventh cause of cancer death in Indonesia in 2020. However, pancreatic cancer is the second leading cause of cancer death in the United States after lung cancer. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive cancer. Pancreatic cancer has multistep carcinogenesis, starting from the Pancreatic Intraductal Neoplasia (PanINs IA, IB, II, and III) and is ended with an invasive neoplastic lesion. The different incidence of pancreatic cancer between countries also shows the important role of environmental factors for the disease. A better understanding of the risk factors, genetics, molecular pathogenesis, symptoms associated with this disease, and the laboratory aspect is essential to inform both health professionals and the general population as the potential preventive and/or early detection measures.

Downloads

Download data is not yet available.

Author Biography

Rikarni Rikarni, Department of Clinical Pathology, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang

Department of Clinical Pathology, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang

References

Kumar V, Abbas AK, Aster JC. Robbins basic pathology. th 10 Ed., Philadelphia, Elsevier, 2018; 686-9.

United States of America. Source Gkobacan 2020. International Agency for Research on Cancer. World

Health Organization. The Global Cancer Observatory, 2021; 1-3.

Indonesia. Source Gkobacan 2020. International Agency for Research on Cancer. World Health Organization. The Global Cancer Observatory, 2021; 1-2.

Asia. Source Gkobacan 2020. International Agency for Research on Cancer. World Health Organization. The Global Cancer Observatory, 2021; 1-2.

McGuigan, Kelly P, Turkington R, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol, 2018; 24(43): 4846-61.

Capasso M, Franceschi M, Castro KIR, Crafa P, Cambie G. Epidemiology and risk factors of pancreatic cancer. Acta Biomed, 2018; 89(9): 141-6.

South-Eastern Asia. Source Gkobacan 2020. International Agency for Research on Cancer. World

Health Organization. The Global Cancer Observatory. 2021; 1-2.

Lahero D, Pancreatic cancer. In: Goldman L, Schafer AI. Goldman–Cecil Medicine. Philadelphia, Elsevier, 2020; 1305-7.

Gzil A, Zarebska I, Burslewiicz W, Antosik P, Grzanka D, Szylberg L. Markers of pancreatic cancer stem cells and their clinical and therapeutic implication. Mol Biol Rep, 2019; 46(6): 6629-45.

Kleef J, Korc M, Apte M, Vecchia CL, Johnson CD, Biankin AV. Pancreatic cancer. Nature Review, 2016;

: 1-22.

Dreyer SB, Chabg DK, Bailey P, Biankin AV. Pancreatic cancer genomes: Implication for clinical management and therapeutic development. Clin Cancer Res, 2017; 23(7): 1638-46.

Shires GT, Wilfong LS. Pancreatic cancer, cystic pancreatic neoplasma. In: Sleisenger and Fordtran's

th Gastrointestinal and Liver Disease. 10 Ed., Philadelpia, Elsevier, 2016; 1027-43.

Siddiqi HA, Salwen MJ, Shaikh MF, Bownw WB. Laboratory diagnosis of gastrointestinal and

pancreatic disorder. In: McPherrson RA, Pincu MR. Henry's clinical diagnosis and management by

laboratory methods. St.Louis, Elsevier, 2017; 306-318.

Gu D, Schlotman KE, Xie J. Deciphering the role of hedgehog signaling in pancreatic cancer. The Journal of Biomedical Research, 2016, 30(5): 353-360.

Khan MA. Azim S, Zubair H, Bhardwaj A, Pate GK, Khusman M. Molecular drivers of pancreatic

pathogenesis: Looking inward to move foreward. Int.J.Mol.Sci, 2017; 18(779): 1-25.

Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DV. Pancreatic cancer: A riddle wraped: In a mystery inside an enigma. Clin Cancer Res, 2017; 23(7): 1629-37.

Marshal WJ, Lapsley M, Day A, Shipman K. Clinical th chemistry. 9 Ed., St.Louis, Elsevier, 2021; 127-130.

Sturgeon A.Tumor markers. In: Tietz fundamental of th clinical chemistry and molecular diagnostic. 8 Ed., St Louis Missouri, Elsevier, 2019; 331-58.

Asamer E, Szkandera J, Gibiser P, Lembeck AL, Stojakovic T. Elevated amylase in plasma represents

adverse prognostic marker in patients with metastatic pancreatic cancer. Wlen Klin Wochenschr, 2018; 130: 569-74.

Flora Melda F, Rahajo B, Arthamin MZ. Pancreatic cancer in 31 years old patient with normal serum

amilase level. Indonesian Journal of Clinical Pathology and Medical Laboratory, 2016; 23(1): 96-101.

Downloads

Submitted

2021-06-13

Accepted

2021-07-29

Published

2021-09-21

How to Cite

[1]
Rikarni, R. 2021. Pancreatic Cancer: Pathogenesis, Diagnosis, and Laboratory Tests. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 27, 3 (Sep. 2021), 333–340. DOI:https://doi.org/10.24293/ijcpml.v27i3.1891.

Issue

Section

Literature Review